interleukin 36 receptor antago

重组人白介素36受体拮抗剂 (IL-36RA)，His标签（无动物源）

货号：PRP1195

产品类型：高纯度重组细胞因子

运输条件：冰袋运输

产品概述

本产品是一种重组表达的人源Interleukin 36受体拮抗剂（IL-36RA），携带His标签，并在无动物源成分的体系中通过大肠杆菌表达系统生产。该蛋白作为一种关键的免疫调节因子，能够特异性拮抗IL-36R信号通路的激活，从而在炎症反应研究中发挥重要作用。

关键特性

• 高纯度与低内毒素：经SDS-PAGE验证，纯度高于98%。每微克蛋白的内毒素含量低于0.1 EU（LAL法检测），适用于对内毒素敏感的细胞功能实验。
• 经功能验证的生物活性：经验证，该蛋白能有效抑制IL-36γ诱导的人外周血单核细胞（PBMC）分泌IL-8，在500 ng/mL IL-36γ存在下，其半数有效浓度（ED₅₀）<2 ng/mL。
• 无动物源表达系统：采用大肠杆菌表达，生产过程中避免引入动物源成分，降低了潜在的外源因子风险。
• 明确的蛋白序列：序列对应人源IL-36RA（UniProt ID: Q9UBH0）的Met1-Asp155氨基酸区域，预测分子量为17.77 kDa。

产品规格

产品形式与保存

• 产品形式：白色或微白色冻干粉末。
• 复溶建议：推荐使用无菌PBS（pH 7.4）作为复溶缓冲液，初始浓度不低于100 µg/mL，以避免聚集，后续可根据实验需求进行稀释。
• 保存建议：冻干粉在-20°C下可稳定保存1年。复溶后于2-8°C可保存最多1周。若在含载体蛋白（如0.1% BSA）的缓冲液中进一步稀释并分装，于-20°C或-80°C下可保存3-6个月，应避免反复冻融。

使用注意事项

• 开盖前请短暂离心试管，以免粉末损失。
• 本品仅供科研使用，不适用于人体或临床诊断。

背景信息

Interleukin-36受体拮抗剂（IL-36RA）是IL-1细胞因子家族的成员，由155个氨基酸残基组成。它主要在淋巴组织和皮肤中表达，并通过拮抗IL-36R信号来抑制促炎反应，在皮肤炎症、银屑病等自身免疫性疾病的研究领域具有重要价值。

基因ID：26525 | 别名：IL36RA, IL-1F5, IL-1HY1, IL-1L1, FIL1δ 等

以上信息基于现有技术资料，具体实验条件请用户根据自身研究体系进行优化。

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

Recombinant Human Interleukin‑36 Receptor Antagonist (IL‑36RA), His‑tag (Animal‑component free)

Product No.: PRP1195

Product Type: High‑purity recombinant cytokine

Shipping Conditions: Ice‑pack shipping

Product Overview

This product is a recombinant‑expressed human Interleukin‑36 receptor antagonist (IL‑36RA) bearing a His‑tag, produced in an animal‑component‑free system using an Escherichia coli expression platform. The protein functions as a pivotal immunoregulatory factor that specifically antagonizes activation of the IL‑36R signaling pathway, thereby playing an essential role in inflammation research.

Key Features

• High purity and low endotoxin: SDS‑PAGE confirmed purity > 98%. Endotoxin levels are < 0.1 EU per µg protein (LAL assay), suitable for endotoxin‑sensitive cellular functional assays.
• Functionally validated bioactivity: The protein effectively inhibits IL‑36γ‑induced IL‑8 secretion from human peripheral blood mononuclear cells (PBMCs), with an ED₅₀ < 2 ng/mL in the presence of 500 ng/mL IL‑36γ.
• Animal‑component‑free expression system: Produced in E. coli, avoiding introduction of animal‑derived constituents and reducing the risk of extraneous factors.
• Defined protein sequence: Corresponds to the human IL‑36RA (UniProt ID: Q9UBH0) residues Met1‑Asp155, with a predicted molecular weight of 17.77 kDa.

Product Specifications

Product Form and Storage

• Form: White or off‑white lyophilized powder.
• Reconstitution recommendation: Dissolve in sterile PBS (pH 7.4) to an initial concentration ≥ 100 µg/mL to minimize aggregation; subsequent dilutions may be made according to experimental requirements.
• Storage recommendation: Lyophilized powder is stable at –20 °C for up to 1 year. Once reconstituted, the solution can be stored at 2–8 °C for a maximum of 1 week. If further diluted in a buffer containing a carrier protein (e.g., 0.1 % BSA) and aliquoted, it may be stored at –20 °C or –80 °C for 3–6 months; avoid repeated freeze‑thaw cycles.

Usage Notes

• Centrifuge the tube briefly before opening to prevent loss of powder.
• This product is intended for research use only and is not suitable for human administration or clinical diagnostics.

Background Information

Interleukin‑36 receptor antagonist (IL‑36RA) is a member of the IL‑1 cytokine family, composed of 155 amino‑acid residues. It is primarily expressed in lymphoid tissues and skin, where it antagonizes IL‑36R signaling to suppress pro‑inflammatory responses. IL‑36RA is therefore of high relevance in studies of cutaneous inflammation, psoriasis, and other autoimmune disorders.

Gene ID: 26525 | Synonyms: IL36RA, IL‑1F5, IL‑1HY1, IL‑1L1, FIL1δ, etc.

The information above is compiled from current technical literature; users should optimize experimental conditions based on their specific systems.

Note: Product details may change with formulation updates or improvements; please consult Yakein Co. for the latest information.